迈威生物-U
(688062)
| 流通市值：116.70亿 | | | 总市值：228.41亿 |
| 流通股本：2.04亿 | | | 总股本：4.00亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 101,165,449.14 | 44,788,452.49 | 199,781,622.22 | 141,095,928.06 |
| 营业收入 | 101,165,449.14 | 44,788,452.49 | 199,781,622.22 | 141,095,928.06 |
| 二、营业总成本 | 671,700,790.36 | 336,094,745.3 | 1,259,798,298.88 | 844,467,620.3 |
| 营业成本 | 21,547,809.1 | 9,975,563.63 | 28,951,667.25 | 10,638,096.49 |
| 税金及附加 | 4,544,810.47 | 1,676,304.11 | 6,051,939.54 | 2,711,149.64 |
| 销售费用 | 102,204,799.24 | 44,745,912.76 | 191,672,154.93 | 168,466,717.93 |
| 管理费用 | 115,046,428.1 | 53,864,887.53 | 213,527,605.44 | 158,902,611.01 |
| 研发费用 | 392,091,498.1 | 208,545,133.67 | 782,869,340.28 | 481,008,266.28 |
| 财务费用 | 36,265,445.35 | 17,286,943.6 | 36,725,591.44 | 22,740,778.95 |
| 其中:利息费用 | 39,311,526.82 | 18,773,815.68 | 57,780,247.68 | 39,149,300.51 |
| 其中:利息收入 | 3,426,731.63 | 1,728,644.68 | 20,916,960.72 | 17,100,314.54 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 18,138.89 | 18,138.89 | 493,457.59 | 210,231.23 |
| 加:投资收益 | -2,865,785.93 | -1,459,211.51 | -4,218,903.47 | -2,716,376.47 |
| 资产减值损失(新) | -7,689,770.12 | -2,718,297.03 | -5,526,750.78 | -8,415,959.33 |
| 信用减值损失(新) | 3,158,532.46 | -498,752.85 | -2,224,140.72 | 2,122,854.37 |
| 其他收益 | 25,471,396.37 | 4,943,462.68 | 28,013,323.4 | 20,136,241.28 |
| 四、营业利润 | -552,442,829.55 | -291,020,952.63 | -1,043,479,690.64 | -692,034,701.16 |
| 加:营业外收入 | 2,189,804.79 | 186.19 | 32,960.54 | 32,840.54 |
| 减:营业外支出 | 1,922,773.06 | 1,382,699.93 | 4,024,748.66 | 2,109,217.92 |
| 五、利润总额 | -552,175,797.82 | -292,403,466.37 | -1,047,471,478.76 | -694,111,078.54 |
| 减:所得税费用 | 54,174 | 54,174 | -906,773.28 | 1,904,086.4 |
| 六、净利润 | -552,229,971.82 | -292,457,640.37 | -1,046,564,705.48 | -696,015,164.94 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -552,229,971.82 | -292,457,640.37 | -1,046,564,705.48 | -696,015,164.94 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -551,319,064.76 | -291,728,135.28 | -1,043,919,217.28 | -694,090,343.42 |
| 少数股东损益 | -910,907.06 | -729,505.09 | -2,645,488.2 | -1,924,821.52 |
| 扣除非经常损益后的净利润 | -573,539,040.67 | -293,423,956.38 | -1,069,605,449.56 | -714,639,561.51 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -1.38 | -0.73 | -2.61 | -1.74 |
| (二)稀释每股收益 | -1.38 | -0.73 | -2.61 | -1.74 |
| 八、其他综合收益 | -42,444.07 | -41,128.07 | 278,847.66 | -1,015,688.86 |
| 归属于母公司股东的其他综合收益 | -42,444.07 | -41,128.07 | 278,847.66 | -1,015,688.86 |
| 九、综合收益总额 | -552,272,415.89 | -292,498,768.44 | -1,046,285,857.82 | -697,030,853.8 |
| 归属于母公司股东的综合收益总额 | -551,361,508.83 | -291,769,263.35 | -1,043,640,369.62 | -695,106,032.28 |
| 归属于少数股东的综合收益总额 | -910,907.06 | -729,505.09 | -2,645,488.2 | -1,924,821.52 |
| 公告日期 | 2025-08-30 | 2025-04-29 | 2025-03-31 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |